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roles in cholesterol metabolism as well as many other bio-
logical functions of HDL particles are dependent on the 
number as well as protein and lipid composition of HDL 
particles. They are poorly reflected by the HDL-C concen-
tration. HDL can even exert negative vascular effects, if its 
composition is pathologically altered. High serum HDL-C 
is therefore no longer regarded protective. In line with this, 
recent pharmacological approaches to raise HDL-C con-
centration have not been able to show reductions of cardio-
vascular outcomes.
Conclusion In contrast to LDL cholesterol (LDL-C), 
HDL-C correlates with cardiovascular risk only in healthy 
individuals. The calculation of the ratio of LDL-C to 
HDL-C is not useful for all patients. Low HDL-C should 
prompt examination of additional metabolic and inflamma-
tory pathologies. An increase in HDL-C through lifestyle 
change (smoking cessation, physical exercise) has positive 
effects and is recommended. However, HDL-C is currently 
not a valid target for drug therapy.
Abstract 
Background While several lines of evidence prove that 
elevated concentrations of low-density lipoproteins (LDL) 
causally contribute to the development of atherosclerosis 
and its clinical consequences, high-density lipoproteins 
are still widely believed to exert atheroprotective effects. 
Hence, HDL cholesterol (HDL-C) is in general still con-
sidered as “good cholesterol”. Recent research, however, 
suggests that this might not always be the case and that a 
fundamental reassessment of the clinical significance of 
HDL-C is warranted.
Method This review article is based on a selective litera-
ture review.
Results In individuals without a history of cardiovascular 
events, low concentrations of HDL-C are inversely associ-
ated with the risk of future cardiovascular events. This rela-
tionship may, however, not apply to patients with metabolic 
disorders or manifest cardiovascular disease. The classical 
function of HDL is to mobilise cholesterol from extrahe-
patic tissues for delivery to the liver for excretion. These 
 * Ulrich Laufs 
 ulrich.laufs@uks.eu
1 Medizinische Klinik V (Nephrologie, Hypertensiologie, 
Rheumatologie, Endokrinologie, Diabetelogie), Medizinische 
Fakultät Mannheim der Universität Heidelberg, Heidelberg, 
Germany
2 Klinisches Institut für Medizinische und Chemische 
Labordiagnostik, Medizinische Universität Graz, Graz, 
Austria
3 Synlab Akademie, synlab Holding Deutschland GmbH, 
Mannheim und Augsburg, Augsburg, Germany
4 Klinik für Innere Medizin IV, Nieren- und 
Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, 
66421 Homburg, Saarland, Germany
5 Klinik für Innere Medizin, Medizinische Universität 
Innsbruck, Innsbruck, Austria
6 Medizinische Klinik II, Klinikum der Universität München, 
81377 Munich, Germany
7 Institut für Klinische Chemie, Universitäts Spital, 
8091 Zurich, Switzerland
8 Klinik für Kardiologie, Charité, Berlin, Germany
9 Klinik für Innere Medizin III, Kardiologie, Angiologie und 
Internistische Intensivmedizin, IMED, Universitätsklinikum 
des Saarlandes, 66421 Homburg, Saarland, Germany
10 Institut für Ernährungswissenschaften, Friedrich Schiller 
Universität Jena, Jena, Germany
 Clin Res Cardiol
1 3
Keywords HDL · Cholesterol · Review
Epidemiology
The concept that high-density lipoproteins (HDL) could 
protect against coronary heart disease (CHD) primarily 
originated from epidemiological studies of the healthy pop-
ulation, in particular the Framingham study [1]. Patients 
with manifest CHD frequently exhibit low HDL choles-
terol (HDL-C) [2]. The relationship between HDL-C and 
cardiovascular risk is not linear; for instance, no further 
improvement in prognosis is seen with HDL-C levels 
above ~60  mg/dl (1.5  mmol/l) (Fig.  1) [3]. Retrospec-
tive investigations of the EPIC Norfolk and of the IDEAL 
study show that very high concentrations of HDL-C 
may be associated with increased risk [4]. A recent reg-
ister study of more than 1  million US veterans found a 
U-shaped relationship between HDL-C and total mortal-
ity with 50  mg/dL (1.25  mmol/L) as the nadir associated 
with the lowest mortality [5]. A very recent analysis of 
the Framingham study reports that the predictive value of 
HDL-C is modified by LDL cholesterol (LDL-C) and tri-
glycerides (TG): Compared to low HDL-C (defined as 
<50 mg/dl in women and <40 mg/dl in men) in isolation, 
risk increases when low HDL-C occurs together with high 
LDL-C and/or TG. Cardiovascular (CV) risk increases 
by 30% for LDL-C ≥ 100  mg/dl and TG < 100  mg/dl or 
LDL-C < 100  mg/dl and TG ≥ 100  mg/dl. When both TG 
and LDL-C are ≥100 mg/dl, CV risk increases by 60% [6].
In summary Low HDL-C is an indicator of increased 
cardiovascular risk, especially in persons without a history 
of cardiovascular events; however, the epidemiological 
relationship between HDL-C and risk is complex. Reduced 
HDL-C concentrations are frequently confounded with 
other pro-atherogenic conditions, notably the presence of 
inflammation and pro-atherogenic triglyceride-rich lipopro-
teins and their remnants as well as small dense LDL. The 
continued widespread practice of calculating the ratio of 
LDL-C to HDL-C is not useful, because high HDL-C is not 
associated with reduced risk, so that a combination of high 
LDL-C and HDL-C may lead to the wrong conclusion that 
risk is not elevated.
Role of HDL in lipoprotein metabolism
HDL are the smallest (5–17  nm) and densest 
(1.063–1.210 kg/l) lipoproteins in the plasma. Apolipopro-
tein (Apo) A1, the major protein in HDL, is synthesised 
in the liver and the small intestine. The liver is the most 
important organ through which cholesterol is excreted, 
either directly or after being converted into bile acids. 
Excess cholesterol is transported from the periphery (e.g. 
from macrophages in blood vessel walls) to the liver. HDL 
play a key role in this pathway, known as reverse choles-
terol transport (RCT) (Fig. 2) [8–11]. In addition to HDL, 
LDL also significantly contribute to RCT. The overwhelm-
ing majority of HDL-C measured in the blood originates 
from the liver and the intestine. Therefore, the concentra-
tion of HDL-C in the plasma cannot be used as a measure 
of cholesterol efflux from vessel walls, or of the efficiency 
of RCT.
The RCT begins with the transfer of cholesterol from 
cell membranes to HDL. To date, four biochemical path-
ways have been described that are involved in this transfer 
[8]. As long as the cholesterol content of the cell is normal, 
more than two-thirds of the (poorly water-soluble, non-
esterified) cholesterol leave the cells by passive diffusion 
along a concentration gradient between the cell membrane 
and preferably large, globular HDL. This concentration 
gradient is maintained by extracellular esterification of free 
cholesterol mediated by the lecithin cholesterol acyltrans-
ferase (LCAT).
Secondly, the passive, aqueous efflux of non-esterified 
cholesterol can be further enhanced by up-regulation of 
ATP-binding cassette transporter G1 (ABCG1). ABCG1 
mobilises cholesterol from subcellular compartments.
Thirdly, passive, but non-aqueous transfer of free choles-
terol from cells to larger HDL can be mediated by the scav-
enger receptor class B type I (SR-B1). SR-B1 promotes not 
only the cellular cholesterol efflux, but also the “selective” 
(i.e. non-endocytotic) delivery of cholesterol from HDL to 
liver cells [12].
Fig. 1  Epidemiological association of low HDL-C serum concentra-
tions with CHD risk. Data from the Emerging Risk Factors Collabo-
ration [3]. With permission of Springer [7]
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Fourthly, cholesterol and phospholipids from mac-
rophages and foam cells are actively transferred to ATP-
binding cassette transporter A1 (ABCA1) to lipid-free 
apo A1 (pre-ß-HDL). This process is important for the 
formation of “nascent” HDL particles, (i.e. HDL discs), 
which contain Apo A1, phosphatidylcholine and non-
esterified cholesterol. The importance of ABCA1 for the 
metabolic maturation of HDL was identified by the eluci-
dation of the genetic cause of Tangier’s disease [13, 14]. 
The expression of ABCA1 is regulated by the intracel-
lular cholesterol content, and efflux mediated by ABCA1 
is therefore important in situations of cellular cholesterol 
excess.
The directed flux of cholesterol between cells and HDL 
is dependent on a concentration gradient between the cell 
membrane and acceptor lipoproteins. This gradient is main-
tained at the cellular level by the hydrolysis of cholesteryl 
esters and translocation of cholesterol, extracellularly by 
lecithin cholesterol acyltransferase (LCAT) and the cho-
lesterol ester transfer protein (CETP). The LCAT esterifies 
free cholesterol (for example, cholesterol associated with 
pre-ß-HDL) with a fatty acid from the lecithin. Cholesteryl 
Fig. 2  Role of HDL in lipoprotein metabolism. Apo A1, the main 
protein in HDL, is formed in the liver and the small intestine and 
secreted as lipid-free pre-ß-HDL. Pre-b-HDL can also come from 
chylomicron metabolism, or from the interconversion of HDL itself. 
Their interaction with ATP-binding cassette transporter A1 (ABCA1) 
leads to the efflux of phosphatidylcholine (PC) and free cholesterol 
(FC), and thus to the formation of disc-shaped HDL. Esterification 
of the free cholesterol by lecithin–cholesterol acyltransferase (LCAT) 
leads to the formation of mature spherical HDL. The lipid-rich dis-
coidal and spherical HDL enable passive diffusion out of cells, which 
is facilitated by ATP-binding cassette transporter G1 (ABCG1), scav-
enger receptor class B type I (SR-B1) and by cholesterol esterification 
mediated by LCAT. Cholesteryl ester transfer protein (CETP) trans-
fers cholesteryl esters (CE), triglycerides and phospholipids (PL) 
between HDL, LDL and VLDL. It thereby contributes to the for-
mation of LDL, which is taken up through LDL receptors (LDLR) 
in hepatocytes. Phospholipid transfer protein (PLTP) belongs to the 
same protein family as CETP. Its function is to transport phospholip-
ids between HDL and VLDL, and between various HDL. Mediated 
by SR-BI, HDL can deliver cholesteryl ester (and free cholesterol) to 
hepatocytes, steroid-producing cells and adipocytes. With permission 
of Springer [7]
 Clin Res Cardiol
1 3
esters are more hydrophobic than free cholesterol and are 
located inside the HDL. This transforms HDL from dis-
coidal into spherical, pseudomicellular particles (α-HDL). 
Maturation of HDL is incomplete in genetic or secondary 
deficiency of LCAT. In patients with familial LCAT defi-
ciency, spherical HDL are absent.
CETP is a hydrophobic glycoprotein which is mainly 
secreted by the liver and is mostly bound to HDL in the 
blood [15]. It facilitates the transfer of cholesteryl esters, 
triglycerides and, to a smaller extent, phospholipids 
between HDL, LDL and VLDL. Thus, cholesteryl esters 
are channelled into the metabolism of LDL and delivered 
to the liver.
In summary HDL-particles play a crucial role in the 
reverse transport and excretion of cholesterol. However, 
HDL-cholesterol measurements do not reflect HDL func-
tion in RCT.
Determination of HDL cholesterol in the clinical 
laboratory
The standard method for the determination of cholesterol in 
LDL and HDL is the combined method of precipitation and 
ultracentrifugation (beta quantification) [16]. In the first 
step, VLDL is recovered by means of ultracentrifugation, 
then LDL is precipitated and finally HDL-C is determined 
enzymatically in the supernatant. This method is not suit-
able for use in the clinical laboratory because of high costs 
and complexity. In the late 1990s, “homogeneous” methods 
were introduced which allow the measurement of HDL-C 
in a single reaction vessel with no prior separation steps 
[17]. In these methods, the cholesterol in non-HDL parti-
cles is “masked” with antibodies, polymers or detergents, 
and in a second reaction step HDL-C is determined enzy-
matically. The commercially available homogeneous assays 
show a good agreement with the reference method in nor-
molipidemic samples and in many cases of hypercholester-
olemia. The determination of HDL-C is hardly affected by 
prior consumption of food and the results can usually well 
be interpreted in post-prandial samples [18]. Differences to 
the reference method and between the assays are, however, 
observed in hypertriglyceridemia (elevated concentrations 
of chylomicrons and/or VLDL), at low HDL-C (<20 mg/
dl), and if atypical lipoproteins are present (type III hyper-
lipoproteinemia, liver disease, chronic kidney disease) 
[19–21]. In these cases, HDL-C can be accurately meas-
ured by lipoprotein electrophoresis, however by staining 
lipoproteins using enzymatic cholesterol oxidation rather 
than unspecific lipophilic chemicals.
Due to the limitations of conventional lipoprotein analy-
sis, researchers are considering the replacement of HDL-C 
and LDL-C determinations with the determination of 
Apo A1 and ApoB, respectively. Measurement of apoli-
poproteins can be readily standardised [22] and is not sig-
nificantly distorted by high triglycerides. Apo B not only 
reflects the concentration of LDL, but all atherogenic lipo-
proteins taken together [VLDL, remnants, LDL, Lp(a)].
In recent years, assays have been introduced which 
reflect the functionality of HDL better than HDL-C. Of 
importance are the determination of HDL particle con-
centrations (and sizes) with nuclear magnetic resonance 
(NMR) spectroscopy [23], the measurement of HDL pro-
teins (Apo A1, serum amyloid A) and the in  vitro meas-
urement of the cholesterol uptake capacity of HDL in cell 
culture models (cholesterol efflux) [24–27]. While the latter 
will most likely remain a research method, NMR and apoli-
poproteins are in principle suitable for routine use, once 
their standardisation has been accomplished.
In summary Current clinically available methods are 
able to determine the cholesterol content of HDL particles, 
but not their biological function. Standardised determi-
nations of HDL-C, and even less so of assays for choles-
terol efflux capacity, HDL particle number determination 
by NMR spectroscopy and HDL proteins, are still not 
satisfactory.
Lesions from genetic abnormality of HDL 
metabolism
Table  1 provides an overview of rare monogenic disor-
ders in the HDL metabolism. According to the results 
from Danish and American population studies, approxi-
mately 10% of individuals with HDL-C levels below the 
5th percentile are heterozygous for mutations in the genes 
of APOA1, ABCA1 or LCAT [28, 29]. Data on the risk of 
atherosclerosis in these individuals are contradictory [30]. 
Some mutations of APOA1 have been associated with 
increased risk of myocardial infarction [31], and another 
one, Apo A1-Milano, may reduce the risk. Some mutations 
of the APOA1 gene also cause familial amyloidosis. In 
large Danish population studies, heterozygosity for HDL-
C-lowering mutations of the ABCA1 or APOA1 gene was 
not associated with an increased risk of myocardial infarc-
tion. Interestingly, ABCA1 mutations increase the risk for 
Alzheimer’s disease. Data from large Dutch family studies 
suggest an increased cardiovascular risk of HDL-C-lower-
ing mutations in the genes of APOA1, ABCA1 or LCAT. 
Italian studies found no evidence for an increased risk of 
atherosclerosis in heterozygous carriers of LCAT mutations 
[32–34].
Homozygous and heterozygous carriers of mutations 
in these three genes are very rare and present themselves 
with pronounced or even complete HDL deficiency and 
characteristic clinical syndromes: patients with complete 
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LCAT deficiency develop corneal opacities, anaemia and 
progressive renal failure, which ultimately requires renal 
replacement therapy. Patients with partial LCAT deficiency 
(“fish eye disease”) develop corneal opacities, but neither 
renal disease nor anaemia. In both cases, the remaining 
HDL are discoidal in shape. In classical LCAT deficiency, 
LDL include particles which are similar to Lipoprotein X 
and may be the cause of the characteristic nephropathy. The 
risk of atherosclerosis of mutation carriers is not increased 
or at most slightly increased [35], possibly because HDL 
can also transport free cholesterol directly to the liver [36].
Homozygosity for mutations in the ABCA1 gene leads 
to Tangier disease [13, 14]. As a result of the strongly 
reduced cellular cholesterol efflux, cholesterol accumulates 
in macrophages in various organs (enlarged tonsils, hepato-
splenomegaly and peripheral neuropathy). Patients with 
Tangier disease often also have low LDL-C, which could 
attenuate the atherogenic effect of the low HDL concentra-
tion [Schaefer, 2010 # 21]. Homozygous nonsense muta-
tions in the APOA1 gene were found to [28] be the cause of 
HDL deficiency in patients with severe xanthomatosis and 
early atherosclerosis.
Most patients with a deficiency of cholesteryl ester trans-
fer protein (CETP) have been observed in Japan. Affected 
persons have very high concentrations of HDL-C. Phar-
macological inhibition of CETP has therefore been tested 
as an approach to increase HDL. It is unclear whether the 
HDL produced through CETP inhibition have a normal 
function. We observed a slightly increased cardiovascu-
lar mortality at low concentrations of CETP in the blood 
despite high HDL-C [37].
Only recently, mutations of scavenger receptor (SR-BI) 
(P279S, P376L) have been described which are associated 
with both significant increases in HDL-C and increased 
cardiovascular risk [38–40]. These mutations impair the 
selective uptake of cholesteryl esters by hepatocytes. In 
mice, the overexpression of SR-B1 leads to an increase in 
RCT, despite a drop in HDL-C [41]. On the other hand, 
lack of SR-BI increases HDL-C, but is atherogenic [42]. 
High HDL-C therefore does not provide protection from 
atherosclerosis in all cases.
This stands in contrast to genetic factors which increase 
LDL cholesterol, because monogenetic (familial hypercho-
lesterolemia) and polygenetic factors increasing LDL cho-
lesterol consistently lead to concordant changes in the CV 
risk (positive Mendelian randomisation) [43, 44].
In summary Current genetic data do not support the con-
cept of a general protective role for HDL-C with regard to 
coronary heart disease.
Disorders with reduced HDL concentration
Compared to genetically determined abnormalities in HDL 
metabolism, low HDL-C much more frequently occur in 
patients with metabolic syndrome or diabetes mellitus. Low 
HDL-C levels are also associated with systemic inflamma-
tion, e.g. with cigarette smoking, chronic inflammatory dis-
eases or chronic kidney disease (Fig. 3) [45, 46]. In cases of 
extremely low HDL-C, rare diagnosis may be considered, 
e.g. neoplasia or an increased risk for sepsis [47, 48].
In summary Low HDL-C is an indicator that the affected 
individual should be examined for metabolic and inflam-
matory pathology.
Vascular protective function of HDL
Evidence has long been available from animal experi-
ments for anti-atherosclerotic effects of HDL. Adminis-
tration of homologous HDL in addition to an atherogenic 
diet inhibits the formation of fatty streaks in rabbits [49]. 
Table 1  Monogenic forms of 
HDL deficiency Mutatedgene Clinical signs with 2 mutated alleles (homozy-gosity, comp. heterozygosity)
Clinical signs with 1 mutated 
allele (heterozygosity)
APOA1 ApoA-I deficiency (OMIM 107680)
Plane xanthoma
Corneal opacity
Early-onset atherosclerosis
Familial amyloidosis
in some variants (OMIM 105200)
(early CHD possible)
ABCA1 Tangier disease (OMIM 205400)
Orange tonsils
Peripheral neuropathy
Hepatosplenomegaly
Early-onset atherosclerosis
None
(Early CHD possible)
LCAT LCAT deficiency (OMIM 245900)
Corneal opacity
Nephropathy (proteinuria, GFR↓)
None
(Early CHD possible)
Fish-eye disease (OMIM126120)
Corneal opacity
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Infusion of Apo A1 Milano (R173C, complexed with 
phospholipids) inhibits atherogenesis in cholesterol-fed 
rabbits [50] and apo E-deficient mice [51].
Alongside its prominent role in RCT, anti-oxidative 
and anti-inflammatory effects are also attributed to HDL, 
as well as improvement of endothelial function [9, 52, 
53]. They inhibit the pathological attachment of mono-
cytes to the endothelium and support endothelial repair 
mechanisms. Many of the endothelial effects of HDL are 
mediated by the endothelial SR-B1 receptor and by the 
bioactive lipid sphingosine-1-phosphate that can act via 
the S1P3 receptor on endothelial cells [54]. Investigations 
of the composition of HDL [55, 56] have found enzymes, 
acute-phase proteins, components of the complement sys-
tem and protease inhibitors in addition to the character-
istic apolipoproteins associated with HDL. The lipidome 
of HDL is even more heterogeneous, and HDL can also 
function as the vehicle for microRNA in the blood [57]. 
Paraoxonase 1 (PON1) is an esterase associated with 
HDL, which inhibits the formation of lipid peroxides in 
LDL [58, 59] and HDL. Compared to healthy people, the 
activity of HDL-associated PON1 is reduced in patients 
with CHD [60]. An anti-oxidative effect is also attributed 
to Apo A1 itself [61]. HDL are anti-inflammatory in sev-
eral ways: they inhibit the expression of adhesion mol-
ecules (VCAM-I and ICAM-I) in the endothelium, inhibit 
the terminal complement complex, inhibit the synthesis 
of chemokines (MCP-1) and induce the expression of the 
anti-inflammatory cytokine transforming growth factor 
beta 2.
In addition, HDL can have antithrombotic and profi-
brinolytic effects [62]. HDL protect from cell damage, 
necrosis and apoptosis. These protective effects have also 
been demonstrated in pancreatic beta cells, implying that 
HDL might be able to improve insulin secretion and protect 
from the development of diabetes mellitus [63–68].
In summary The anti-inflammatory, cytoprotective and 
wound-healing effects of HDL make them a part of the 
innate host defense system [69]. From an evolutionary 
point of view, the potential anti-atherogenic effects, if any 
of them exist, would likely be secondary.
HDL dysfunction
Interestingly, several studies have provided evidence that 
the vascular effects of HDL are variable and hardly corre-
late with HDL-C concentrations in the plasma. In patients 
with diabetes mellitus, coronary disease, chronic renal 
insufficiency, cardiovascular risk factors and disorders, the 
function of HDL is impaired [9, 61, 70–74]. In patients who 
underwent coronary angiography, we have observed that 
HDL-C correlates inversely with cardiovascular mortality 
in the absence of CHD, that the relationship of HDL-C to 
long-term prognosis was weakened in stable coronary heart 
disease, whereas in clinically unstable patients the relation-
ship was completely abolished [74].
The protein composition of HDL changes significantly 
in the course of an acute-phase reaction. The “acute-phase 
HDL” are characterised, for example, by increased concen-
trations of serum amyloid A (SAA), secretory phospholi-
pase A2 (sPLA2-IIa) and ceruloplasmin, and a lower pro-
portion of Apo A1 [73]. Unlike HDL from healthy subjects, 
HDL from patients with CHD, kidney disease or diabetes 
mellitus have no protective vascular effects or may even 
cause paradoxical harmful effects [55, 56, 61, 70, 71, 75, 
76]. The characterisation of the HDL’s “milieu” may offer 
an opportunity for determining the function of HDL. For 
example, HDL-C corrected by the SAA concentration cor-
relates with risk better than HDL-C alone in several inde-
pendent cohorts [77].
Another way to determine the functionality of HDL in 
the laboratory, although one that requires more efforts, is 
measuring cellular cholesterol efflux. In this method, cul-
tivated cells are enriched with labelled cholesterol and 
incubated with Apo B-free serum from the patient, and 
the rate of transfer of labelled cholesterol into the patient 
serum is determined. The rate of cholesterol efflux has been 
associated with the prevalence of CHD, independent of the 
HDL-C concentration [24], with cardiovascular events and 
deaths (Fig.  4) [25, 26]. In another study, cellular efflux 
was inversely correlated with prevalent atherosclerosis, but 
not with the long-term risk of cardiovascular events [78].
low 
HDL 
Genetics 
Hyper- 
triglyceridemia  
Diabetes & 
Obesity 
Inflammatory & 
hemato-oncologic 
diseases 
Liver & intestinal 
diseases, storage 
diseases 
Medication & 
Hormones  
Fig. 3  Aetiologies of low HDL cholesterol. With permission of 
Springer [7]
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In summary The biological function of HDL is in part 
dependent on their protein composition. The properties of 
HDL are poorly reflected by their cholesterol content. In 
disease states, HDL may turn dysfunctional and can even 
have negative vascular effects.
Should HDL‑C be increased by therapeutic 
measures?
The positive vascular effects of HDL have been an attrac-
tive target for the treatment of chronic or acute vascular dis-
ease. Approaches to increase HDL include lifestyle modi-
fications, conventional pharmacological therapy and novel 
therapeutic modalities which are still under scrutiny.
Lifestyle
HDL-C can be increased through a number of lifestyle 
changes [79] (Table  2). The most important among these 
are increased physical activity and dietary changes. Life-
style changes that increase HDL-C are also associated with 
reduced risk of cardiovascular disease [80]. The actual con-
tributions made by increases in HDL-C are however not 
clear, because these interventions do not increase HDL-C 
in isolation, but influence metabolism in a variety of ways. 
Physical activity not only leads to an increase in HDL-C, 
but also to changes in HDL functionality [69]. At the same 
time, the metabolism of triglyceride-rich lipoproteins (fast-
ing and postprandial) is improved [81, 82]. Yet, a number 
of other pathologies are also subject to positive changes 
(e.g. insulin sensitivity). We therefore conclude that the 
Fig. 4  Cellular cholesterol 
efflux and cardiovascular 
mortality. Kaplan–Meier curves 
and hazard ratios by quartiles 
of cholesterol efflux capacity. 
Model 1: adjusted for age and 
gender; Model 2: also adjusted 
for use of lipid-lowering drugs, 
CHD (none, stable, unstable 
CHD, NSTEMI, STEMI), 
body mass index, hyperten-
sion, smoking, LDL-C/HDL-C 
ratio, triglycerides, metabolic 
syndrome/type 2 diabetes mel-
litus [26]. With permission of 
Springer [7]
Table 2  Influence of lifestyle 
modifications on HDL-C
ABCA1 ATP-binding cassette transporter A1, ABCG1 ATP-binding cassette transporter G1, CETP choles-
teryl ester transfer protein, LCAT lecithin–cholesterol acyltransferase, LPL lipoprotein lipase
Intervention HDL-C increa-
sein %
Effect
Physical activity 5–10 Increased LPL, pre-β-HDL, reverse cholesterol transport, 
protective lipoproteins
Smoking cessation 5–10 Increased LCAT, reverse cholesterol transport, inhibits CETP
Weight loss 5–20 Increased LCAT, LPL and reverse cholesterol transport
Alcohol consumption 5–15 Increased ABCA1, apo-A-I and paraoxonase, reduced CETP
Mediterranean diet 
(unsaturated fatty acids)
0–5 Increase in atheroprotective lipoproteins
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increase in HDL-C observed with lifestyle changes repre-
sents a marker of reduced cardiovascular risk.
Statins
Statins competitively inhibit HMG-CoA reductase, the 
rate-limiting enzyme for cholesterol biosynthesis, and they 
reduce LDL-C. Statins also lower triglycerides and slightly 
raise HDL-C. It is unlikely that this increase in HDL-C 
makes a substantial contribution to the reduction of events 
mediated by statins [83–85].
Fibrates
Fibrates are agonists of the nuclear receptor PPAR-α (per-
oxisome proliferator-activated receptor alpha). Fibrates 
stimulated the expression of Apo A1 and via LXR the 
expression of ABCA1. Fibrates also up-regulate SR B1, 
which mitigates their HDL-raising effect, but is synergistic 
in activating RCT. Fibrates also activate lipolytic enzymes, 
lipoprotein lipase (LPL) in particular, which leads to 
increased catabolism of triglyceride-rich lipoproteins and 
an indirect increase in HDL-C.
A meta-analysis of 18 prospective, randomised outcome 
studies concluded that fibrates reduce the rate of severe car-
diovascular events by 10% and the progression of albumi-
nuria by 14% [86]. It is unclear whether the clinical effects 
of fibrates are due primarily to the increase in HDL-C, the 
decrease in triglycerides or the slight reduction in LDL. For 
patients with diabetes mellitus and statin therapy, fibrates 
have not been shown to provide any further reduction of 
risk [87–89]. Retrospective analyses of fibrate trials raise 
the possibility that reductions in risk can be achieved in 
subgroups with atherogenic dyslipidemia (high triglyc-
erides and low HDL-C) [88, 90, 91]. In Phase 3 studies 
with new fibrates, this hypothesis is being tested prospec-
tively. If these studies were successful, the use of fibrates in 
patients with high triglycerides and/or low HDL-C would 
be warranted.
Niacin
Niacin and derivatives reduce triglycerides, VLDL choles-
terol, LDL-C and lipoprotein (a), and they increase HDL-
C. Among other factors, the effects are based on the inhi-
bition of hepatic diacylglycerol acyltransferase 2, a key 
enzyme in the synthesis of triglycerides. Meta-analyses of 
studies with niacin (mostly without simultaneous admin-
istration of statins) indicate a decrease in cardiovascular 
events [92–94]. A subsequent meta-analysis of 11 outcome 
studies, which were mainly conducted in secondary preven-
tion and included the AIM-HIGH-study [92], indicated that 
niacin reduced cardiovascular events and adverse coronary 
endpoints by 34 and 25%, respectively [94].
A combination of niacin with laropiprant was tested 
on 25,673 patients in the HPS2-THRIVE study [95]. No 
reduction in vascular events was observed, but the rates of 
severe side effects such as bleeding, myopathy, infections 
and diabetes mellitus increased. Since then, niacin prepara-
tions are no longer available in Europe. Based on the AIM-
HIGH, ACCORD and HPS2-THRIVE studies, the Federal 
Drug Administration has come to the conclusion that there 
is no sufficient evidence for the reduction of cardiovascular 
events through the use of fibrates and niacin [96, 97], espe-
cially in conjunction with statin therapy.
CETP inhibition
Cholesteryl ester transfer protein (CETP) mediates the 
exchange of cholesterol and triglycerides between vari-
ous lipoproteins and thus plays an important role in RCT 
(Fig. 2) [98, 99]. The concept of CETP inhibition is based 
on the following observations: rodents are naturally CETP 
deficient, display high HDL-C and are resistant to diet-
induced atherosclerosis. Patients with genetically reduced 
or absent CETP activity have high HDL-C. Inhibition of 
CETP has a positive influence on the lipoprotein profile in 
humans and could therefore show atheroprotective effects.
However, animal experiments have yielded contradic-
tory results. In rabbits, CETP inhibition led to a reduc-
tion in atherosclerosis. In mice, both atheroprotective and 
atherogenic effects have been reported. Studies in humans 
have also been contradictory. On the one hand, patients 
with genetically reduced CETP serum concentrations 
appear to have a slightly reduced risk of coronary heart dis-
ease [99–102]. On the other hand, many studies in which 
CETP was tested in the plasma showed an inverse corre-
lation between CETP and cardiovascular risk [37, 103]. 
Drug-based inhibition of CETP in humans leads to a signif-
icant increase in HDL-C and a drop in LDL-C [104, 105]. 
However, three out of four prospective studies with CETP 
inhibitors had to be terminated due to increased mortality 
in the treatment group or due to futility (Table 3). (https://
investor.lilly.com/releasedetail.cfm?ReleaseID=936130) 
[106, 107]. The results of the large HPS-3/TIMI55 study, 
including over 30,000 patients, are pending.
One reason for the disappointing performance of CETP 
inhibitors thus far could be the fact that the transfer of cho-
lesteryl esters from HDL to LDL, and thus a pivotal step 
in RCT, is being inhibited. CETP inhibition probably also 
extends the lifespan of dysfunctional HDL. This may not 
only eliminate the postulated atheroprotective effect but 
even be harmful if HDL gained adverse properties [9, 
74, 108]. Future strategies may include the identification 
of patients who benefit from CETP inhibition. Another 
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alternative approach would be the development of new 
inhibitors that reduce CETP production or modification of 
CETP function [109].
Other HDL‑boosting drugs in development
Recent approaches primarily aim to optimise the func-
tion of HDL in RCT [110, 111]. Although HDL likely 
influences atherogenesis in a variety of ways, the focus 
is on the HDL-dependent aspects of RCT (Table 4). For 
instance, some such approaches use artificial discoi-
dal HDL which, in addition to phospholipids, contain 
Apo A1 (CSL112) isolated from plasma, recombinant 
Apo A1 (CER001) or variant Apo A1 (Apo A1 Milano). 
Others generate pre-beta HDL via delipidation of the 
patient’s own plasma [111]. Both in  vitro and in  vivo, 
these approaches can achieve a transient acceleration of 
RCT, sometimes without causing any significant change 
in HDL-C. One problem is at present, however, that there 
is still no simple biomarker available for HDL function-
ality. The further development of Apo A1 Milano has 
been stopped in 2016 due to lack of efficacy [112]. How-
ever, the search for other possible ways to intensify RCT 
remains the subject of ongoing research.
In summary An increase in HDL-C through lifestyle 
changes has positive effects and is recommended. This is 
especially true for smoking cessation and physical activ-
ity. Outcome studies with fibrates and with niacin have 
been conducted to evaluate the potential of HDL-C as a 
therapeutic target. However, since these drugs also cause 
drops in triglycerides and (to a moderate extent) LDL-C, 
neither fibrates nor niacin can conclusively value HDL-C 
as a drug target. There is no evidence for a reduction in 
clinical events through niacin or fibrates in combination 
with statins. In the studies available to date, increasing 
HDL-C with CETP inhibitors has not led to a reduction 
in clinical events. We conclude that HDL-C is not a target 
for drug-based therapy at the present time.
Table 3  Prospective clinical 
intervention studies with CETP 
inhibitors
CETP cholesteryl ester transfer protein
CETP inhibitor Study Patients Started Result
Torcetrapib ILLUMINATE ca. 15,000 2004 Cut short in 2006 due to increased 
mortality in the treatment group
Dalcetrapib Dal-OUTCOMES ca. 15,000 2008 Cut short in 2012 due to lack of effect
Anacetrapib REVEAL ca. 30,000 2011 Results expected in early 2017
Evacetrapib ACCELERATE ca. 11,000 2012 Cut short in 2015 due to lack of effect
Table 4  HDL-modifying substances in clinical trials
APOAI apolipoprotein 1, CETP cholesteryl ester transfer protein, LCAT lecithin–cholesterol acyltransferase. Modified as per B.A. Kingwell et al. 
[110]
Drug (Manufacturer) Properties Development status
RVX-208 (Resverlogix) Substance stimulates APOA1 transcription Phase IIb IVUS study neutral [113]
CER-001 (Cerenis) HDL mimetic produced from recombinant APOA1 
complexed with phospholipids
IVUS-Study neutral, additional 
studies ongoing [114]
CSL111 (CSL Behring) HDL mimetic produced from human APOA1 recon-
stituted with phospholipids
Further development cancelled
CSL112 (CSL Behring) HDL mimetic produced from human APOA1 recon-
stituted with phospholipids
Replaces CSL 111
Recombinant APOA1 Milano; ETC-216, now 
MDCO-216
(The Medicines Company)
Natural mutation variant of APOA1, associated with 
a low rate of cardiovascular disease
Development stopped late 2016 111
APP018 (Bruin Pharma, licenced to Novartis in 
2005)
Oral APOA1 mimetic (peptide), also known as 
D-4F
Current development status unclear
Delipidated HDL Low-lipid HDL, produced by selective delipidation 
of HDL; can be used by autologous reinfusion 
(aphaeresis)
Current development status unclear
ACP-501 (AlphaCore Pharma, recently taken over 
by MedImmune)
Recombinant, human LCAT Tested in Phase I study
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Practical consequences
HDL play a central role in RCT. Large epidemiological 
studies have found an inverse relationship between the con-
centration of HDL-C in plasma and CHD. Mendelian ran-
domisation studies show no protective effects of a geneti-
cally high HDL-C concentration. Cholesterol transported 
with HDL neither has any protective function nor reflects 
the functionality of HDL. HDL particles as such, as well 
as specific proteins and lipids in HDL, contribute to the 
classical functions of HDL in RCT, or mediate their anti-
oxidative and anti-inflammatory properties. HDL composi-
tion is modified in complex ways in acute and chronic dis-
eases. In this sense, it is misleading to interpret HDL-C as 
being equivalent to HDL or “good cholesterol”. The deter-
mination of pathophysiologically relevant lipids or proteins 
associated with HDL may come to replace HDL-C in the 
future, but at present such assays are not yet available for 
routine clinical use [9, 115]. The following clinical conse-
quences result from these new findings:
•	 Low HDL-C is often a clinical indicator of disturbed 
metabolism of triglyceride-rich lipoproteins (e.g. in dia-
betes mellitus) or a chronic inflammation.
•	 The prognosis with regard to cardiovascular disease 
cannot be determined via HDL-C; the ratio of HDL-C 
to LDL-C may be misleading if HDL-C is high and if 
comorbidities like CHD, diabetes mellitus or chronic 
kidney disease exist.
•	 Increasing HDL-C through lifestyle factors such as 
physical activity and smoking cessation is associated 
with vascular protective effects.
•	 At present, HDL-C is not a target for drug-based treat-
ment. The primary goal of lipid therapy is currently the 
reduction of LDL cholesterol.
Clearly, the “HDL-Cholesterol story” is not over but the 
recent findings set the stage for future research on this com-
plex lipopoprotein.
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